[1] WIJESURENDRA D S, KANCI A, TIVENDALE K A, et al. Development of a Mycoplasma gallisepticum infection model in turkeys[J]. Avian Pathol, 2015, 44(1):35-42.
[2] LEMCKE R M. The serological differentiation of Mycoplasma strains (pleuropneumonia-like organisms) from various sources[J]. Epidemiol Infect, 1964, 62(2):199-219.
[3] LEVISOHN S, KLEVEN S H. Avian mycoplasmosis (Mycoplasma gallisepticum)[J]. Rev Sci Tech, 2000, 19(2):425-442.
[4] DHONDT A A, DHONDT K V, NAZERI S. Apparent effect of chronic Plasmodium infections on disease severity caused by experimental infections with Mycoplasma gallisepticum in house finches[J]. Int J Parasitol Parasites Wildl, 2017, 6(2):49-53.
[5] XIAO X, SUN J, CHEN Y, et al. Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6 in Mycoplasma gallisepticum and Escherichia coli co-infected chickens[J]. Vet J, 2015, 204(1):54-59.
[6] XIAO X, ZHAO D H, YANG X, et al. Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics[J]. J Vet Pharmacol Ther, 2014, 37(1):99-102.
[7] CHIU C H, SU L H, CHU C. Salmonella enterica serotype choleraesuis:epidemiology, pathogenesis, clinical disease, and treatment[J]. Clin Microbiol Rev, 2004, 17(2):311-322.
[8] SHIL P K, KANCI A, BROWNING G F, et al. Development and immunogenicity of recombinant GapA⁺ Mycoplasma gallisepticum vaccine strain ts-11 expressing infectious bronchitis virus-S1 glycoprotein and chicken interleukin-6[J]. Vaccine, 2011, 29(17):3197-3205.
[9] HUTTON S, BETTRIDGE J, CHRISTLEY R, et al. Detection of infectious bronchitis virus 793B, avian metapneumovirus, Mycoplasma gallisepticum and Mycoplasma synoviae in poultry in Ethiopia[J]. Trop Anim Health Prod, 2016, 49(2):317-322.
[10] FEBERWEE A, MEKKES D R, DE WIT J J, et al. Comparison of culture, PCR, and different serologic tests for detection of Mycoplasma gallisepticum and Mycoplasma synoviae infections[J]. Avian Dis, 2005, 49(2):260-268.
[11] MUNETA Y, PANICKER I S, KANCI A, et al. Development and immunogenicity of recombinant Mycoplasma gallisepticum vaccine strain ts-11 expressing chicken IFN-γ[J]. Vaccine, 2008, 26(43):5449-5454.
[12] PREZOTTO C F, MARIN S Y, ARAÚJO T S, et al. Experimental coinfection of chicken anemia virus and Mycoplasma gallisepticum vaccine strains in broiler chicks[J]. Rev Bras Cienc Avic, 2016, 18(3):475-480.
[13] LEIGH S A, BRANTON S L, EVANS J D, et al. Impact of fowlpox-vectored Mycoplasma gallisepticum vaccine Vectormune FP MG on layer hen egg production and egg quality parameters[J]. Poult Sci, 2013, 92(12):3172-3175.
[14] ZHANG N, YE X M, WU Y Z, et al. Determination of the mutant selection window and evaluation of the killing of Mycoplasma gallisepticum by danofloxacin, doxycycline, tilmicosin, tylvalosin and valnemulin[J]. PLoS One, 2017, 12(1):e0169134.
[15] OSEI SEKYERE J, AMOAKO D G. Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa[J]. PLoS One, 2017, 12(6):e0178888.
[16] LIU X Q, LIU H X, LI Y Q, et al. Association between virulence profile and fluoroquinolone resistance in Escherichia coli isolated from dogs and cats in China[J]. J Infect Dev Countr, 2017, 11(4):306-313.
[17] TATAY-DUALDE J, PRATS-VAN DER HAM M, DE LA FE C, et al. Mutations in the quinolone resistance determining region conferring resistance to fluoroquinolones in Mycoplasma agalactiae[J]. Vet Microbiol, 2017, 207:63-68.
[18] 魏飞龙, 周云雷, 沈祥广, 等. 耐氟喹诺酮类药物鸡毒支原体DNA回旋酶及拓扑异构酶Ⅳ的突变特征[J]. 中国畜牧兽医, 2010, 37(9):43-47.
WEI F L, ZHOU Y L, SHEN X G, et al. Characterization of mutations in DNA gyrase and topoisomerase Ⅳ involved in Quinolone resistance of clinical Mycoplasma gallisepticum isolates[J]. China Animal Husbandry & Veterinary Medicine, 2010, 37(9):43-47. (in Chinese)
[19] LI J, LU D H, LIU Z J, et al. Role of mutations in DNA gyrase and topoisomerase IV in fluoroquinolones-resistance of Mycoplasma gallisepticum obtained in vitro and in vivo[J]. J Anim Vet Adv, 2012, 11(13):2327-2332.
[20] JOHNNING A, KRISTIANSSON E, FICK J, et al. Resistance mutations in gyrA and parC are common in Escherichia communities of both fluoroquinolone-polluted and uncontaminated aquatic environments[J]. Front Microbiol, 2015, 6:1355.
[21] SAMUEL S O, ABODERIN A O, SALAMI T A T, et al. Campylobacter antimicrobial drug resistance among humans in Ilorin, Nigeria[J]. Niger Med J, 2007, 48(3):75-77.
[22] STASS H, DALHOFF A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints[J]. Infection,2005,33(S2):29-35.
[23] 马越, 李景云, 金少鸿. 美国临床实验室标准委员会推荐药敏试验操作方法和判断标准(2005年修订版)[J]. 中华医学杂志, 2005, 85(17):1182-1184.
MA Y, LI J Y, JIN S H. Clinical Laboratory Standards Committee recommends methods of drug susceptibility testing standards of judgment (2005 Revision)[J]. National Medical Journal of China, 2005, 85(17):1182-1184. (in Chinese)
[24] BROWN D, MACGOWAN A. Harmonization of antimicrobial susceptibility testing breakpoints in Europe:implications for reporting intermediate susceptibility[J]. J Antimicrob Chemother, 2010, 65(2):183-185.
[25] TURNIDGE J, KAHLMETER G, KRONVALL G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values[J]. Clin Microbiol Infect, 2006, 12(5):418-425.
[26] BÖTTNER A, DE JONG A, SCHMID P, et al. Determination of breakpoints for veterinary medically relevant antibiotics for resistance assessment of veterinary pathogens[J]. Berl Münch Tierarztl Wochenschr, 2000, 113(9):344-347.
[27] 童明庆. 抗菌药的PK/PD理论及其在新抗菌药的药效研究中应用[J]. 中国临床药理学杂志, 2008, 24(5):475-480.
TONG M Q. PK/PD theory of antibiotic and its application in study on Pharmacodynamics of new antibiotic[J]. The Chinese Journal of Clinical Pharmacology, 2008, 24(5):475-480. (in Chinese)
[28] BYWATER R, SILLEY P, SIMJEE S. Antimicrobial breakpoints-definitions and conflicting requirements[J]. Vet Microbiol, 2006, 118(1-2):158-159.
[29] 郭伟娜. 鸡毒霉形体不同菌株的药敏实验及耐药机制的研究[D]. 武汉:华中农业大学, 2007.
GUO W N. Study on the susceptibility and resistance mechanism of different strains of Mycoplasma gallisepticum to antibiotic drugs[D]. Wuhan:Huazhong Agricultural University, 2007. (in Chinese)
[30] BARBERIO A, FLAMINIO B, DE VLIEGHER S, et al. Short communication:In vitro antimicrobial susceptibility of Mycoplasma bovis isolates identified in milk from dairy cattle in Belgium, Germany, and Italy[J]. J Dairy Sci, 2016, 99(8):6578-6584.
[31] LANDMAN W J M, MEVIUS D J, VELDMAN K T, et al. In vitro antibiotic susceptibility of Dutch Mycoplasma synoviae field isolates originating from joint lesions and the respiratory tract of commercial poultry[J]. Avian Pathol, 2008, 37(4):415-420.
[32] THONGKAMKOON P, NARONGSAK W, KOBAYASHI H, et al. In vitro susceptibility of Mycoplasma hyopneumoniae field isolates and occurrence of fluoroquinolone, macrolides and lincomycin resistance[J]. J Vet Med Sci, 2013, 75(8):1067-1070.
[33] SULYOK K M, KREIZINGER Z, FEKETE L, et al. Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe[J]. BMC Vet Res, 2014, 10:256.
[34] GRÓZNER D, KREIZINGER Z, SULYOK K M, et al. Antibiotic susceptibility profiles of Mycoplasma sp. 1220 strains isolated from geese in Hungary[J]. BMC Vet Res, 2016, 12:170.
[35] JENSEN J S, FERNANDES P, UNEMO M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains[J]. Antimicrob Agents Chemother, 2014, 58(6):3151-3156.
[36] HEUVELINK A, REUGEBRINK C, MARS J. Antimicrobial susceptibility of Mycoplasma bovis isolates from veal calves and dairy cattle in the Netherlands[J]. Vet Microbiol, 2016, 189:1-7.
[37] DUFFY L B, CRABB D M, BING X, et al. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae[J]. J Antimicrob Chemother, 2003, 52(3):527-528.
[38] KRAUSSE R, SCHUBERT S. In vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years[J]. Clin Microbiol Infect, 2010, 16(11):1649-1655.
[39] PATERNA A, SÁNCHEZ A, GÓMEZ-MARTÍN A, et al. Short communication:in vitro antimicrobial susceptibility of Mycoplasma agalactiae strains isolated from dairy goats[J]. J Dairy Sci, 2013, 96(11):7073-7076.
[40] KIDANEMARIAM A, GOUWS J, VAN VUUREN M, et al. In vitro antimicrobial susceptibility of Mycoplasma mycoides mycoides large colony and Arcanobacterium pyogenes isolated from clinical cases of ulcerative balanitis and vulvitis in Dorper sheep in South Africa[J]. J South Afr Vet Assoc, 2005, 76(4):204-208.
[41] GERCHMAN I, LYSNYANSKY I, PERK S, et al. In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys[J]. Vet Microbiol, 2008, 131(3-4):266-276.
[42] LYSNYANSKY I, AYLING R D. Mycoplasma bovis:mechanisms of resistance and trends in antimicrobial susceptibility[J]. Front Microbiol, 2016, 7:595.
[43] BÉBÉAR C M, RENAUDIN H, SCHAEVERBEKE T, et al. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas[J]. J Antimicrob Chemother, 1999, 43(5):711-714.
[44] WAITES K B, CRABB D M, DUFFY L B. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae[J]. Int J Antimicrob Agents, 2003, 21(6):574-577.
[45] 林居纯, 曾振灵, 吴聪明. 鸡毒支原体的耐药性调查[J]. 中国兽医杂志, 2008, 44(8):40-41.
LIN J C, ZENG Z L, WU C M. Investigation of drug resistance of Mycoplasma gallisepticum isolates[J]. Chinese Journal of Veterinary Medicine, 2008, 44(8):40-41. (in Chinese)
[46] 戴自英. 临床抗菌药物学[M].北京:人民卫生出版社, 1985.
DAI Z Y. Clinical antibacterial pharmacology[M]. Beijing:People's Medical Publishing House, 1985. (in Chinese)
[47] 向蓉, 丁焕中, 曾振灵. 鸡源大肠杆菌、支原体对几种抗菌药物的耐药性调查[J]. 养禽与禽病防治, 2006(11):21-22, 17.
XIANG R, DING H Z, ZENG Z L. Investigation on resistance of Escherichia coli and Mycoplasma to several Antibiotics in chicken[J]. Poultry Husbandry and Disease Control, 2006(11):21-22, 17. (in Chinese)
[48] MUSTAFA R, QI J J, BA X L, et al. In vitro quinolones susceptibility analysis of Chinese Mycoplasma bovis isolates and their phylogenetic scenarios based upon QRDRs of DNA topoisomerases revealing a unique transition in ParC[J]. Pak Vet J, 2013, 33(3):364-369.
[49] KHALIL D, BECKER C A, TARDY F. Alterations in the quinolone resistance determining regions and fluoroquinolone resistance in clinical isolates and laboratory-derived mutants of Mycoplasma bovis:not all genotypes may be equal[J]. Appl Environ Microbiol, 2015, 82(4):1060-1068.
[50] MENG D Y, SUN C J, YU J B, et al. Molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis clinical isolates[J]. Braz J Microbiol, 2014, 45(1):239-242.
[51] MURRAY G L, BRADSHAW C S, BISSESSOR M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium[J]. Emerg Infect Dis, 2017, 23(5):809-812.
[52] DUMKE R, THVRMER A, JACOBS E. Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany[J]. Diagn Microbiol Infect Dis, 2016, 86(2):221-223.
[53] SATO T, OKUBO T, USUI M, et al. Amino acid substitutions in GyrA and ParC are associated with fluoroquinolone resistance in Mycoplasma bovis isolates from Japanese dairy calves[J]. J Vet Med Sci, 2013, 75(8):1063-1065.
[54] 刘玉庆, 李璐璐,骆延波, 等. EUCAST欧盟药敏试验标准[M]. 北京:中国质检出版社, 2016.
LIU Y Q, LI L L, LUO Y B, et al. EUCAST EU drug susceptibility testing standards[M]. Beijing:China Quality Inspection Press, 2016. (in Chinese)
[55] DIMITROVA D J, LASHEV L D, YANEV S G, et al. Pharmacokinetics of enrofloxacin in turkeys[J]. Res Vet Sci, 2007, 82(3):392-397.
[56] GBERINDYER F A, WANNANG N, AKWUOBU C A. Comparative pharmacokinetics/pharmacodynamic modeling on three brands of 10% enrofloxacin oral formulations in broiler chickens[J]. Int J Poult Sci, 2010, 9(3):273-277.
[57] HARITOVA A M, RUSENOVA N V, PARVANOV P R, et al. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys[J]. Antimicrob Agents Chemother, 2006, 50(11):3779-3785.
[58] IVANOVA S, DIMITROVA D, PETRICHEV M. Pharmacokinetics of ciprofloxacin in broiler chickens after single intravenous and intraingluvial administration[J]. Mac Vet Rev, 2017, 40(1):67-72.
[59] 张秀英, 佟恒敏, 丛霞, 等. 单诺沙星在雏鸡体内的药动学特征及生物利用度研究[J]. 黑龙江畜牧兽医, 2001(9):3-4.
ZHANG X Y, TONG H M, CONG X, et al. Studies on the pharmacokintics and bioavailability of Danofloxacin in chickens[J]. Heilongjiang Journal of Animal Science and Veterinary Medicine, 2001(9):3-4. (in Chinese)
[60] 王睿. 氟喹诺酮类PK/PD的研究进展[J]. 中国新药杂志, 2002, 11(11):884-887.
WANG R. The rearch progress of pharmacokinetics/pharmacodynamics in fluoroquinolones[J]. Chinese Journal of New Drugs, 2002, 11(11):884-887. (in Chinese)
[61] DIMITROVA D J, HARITOVA A M, DINEV T D, et al. Comparative pharmacokinetics of danofloxacin in common pheasants, guinea fowls and Japanese quails after intravenous and oral administration[J]. Br Poult Sci, 2014, 55(1):120-125.
[62] DEVADA S S, PATEL S D, PATEL H B, et al. Pharmacokinetics of gatifloxacin in broiler chickens following intravenous and oral administration[J]. Br Poult Sci, 2012, 53(2):257-261.
[63] LEES P. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat[J]. J Vet Pharmacol Ther, 2013, 36(3):209-221.
[64] SRIRANJANI D, KALAISELVI L, RAMESH S, et al. Pharmacokinetics of sparfloxacin in broiler chicken[J]. Br Poult Sci, 2006, 47(6):720-725.
[65] ALBARELLOS G A, KREIL V E, LANDONI M F. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats[J]. J Vet Pharmacol Ther, 2004, 27(3):155-162.
[66] SHI F, TANG H, XIE W, et al. Pharmacokinetic study of enrofloxacin in Tianfu geese[J]. J Anim Plant Sci, 2014, 24(1):113-119.
[67] GOUDAH A, HASABELNABY S. Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration[J]. Res Vet Sci, 2010, 88(3):507-511.
[68] MARÍN P, ÁLAMO L F, ESCUDERO E, et al. Pharmacokinetics of marbofloxacin in rabbit after intravenous, intramuscular, and subcutaneous administration[J]. Res Vet Sci, 2013, 94(3):698-700.
[69] DIMITROVA D, KATSAROV V, TSONEVA D. Pharmacokinetics of pefloxacin in pigs after single intramuscular application[J]. Agric Sci Technol, 2012, 4(3):215-219.
[70] KALAISELVI L, SRIRANJANI D, RAMESH S, et al. Pharmacokinetics of ofloxacin in broiler chicken[J]. J Vet Pharmacol Ther, 2006, 29(3):185-189.
[71] ANADÓN A, SUÁREZ F H, MARTÍNEZ M A, et al. Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening[J]. Food Chem Toxicol, 2011, 49(2):441-449.
[72] VARIA R D, PATEL J H, PATEL U D, et al. Disposition of levofloxacin following oral administration in broiler chickens[J]. Israel J Vet Med, 2009, 64(4):118-121.
[73] EL GARCH F, DE JONG A, SIMJEE S, et al. Monitoring of antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009-2012:VetPath results[J]. Vet Microbiol, 2016, 194:11-22.
[74] 刘明春,佟恒敏,何剑斌, 等.司帕沙星对实验性感染鸡大肠杆菌-败血霉形体病的药效学研究[J].沈阳农业大学学报,2004,35(3):231-234.
LIU M C, TONG H M, HE J B, et al. Pharmacodynamical studies of sparfloxacin against experimentally induced E. coli-mycoplasma disease chickens[J]. Journal of Shenyang Agricultural University, 2004, 35(3):231-234. (in Chinese)
[75] 张秀英, 郭文欣, 佟恒敏, 等. 单诺沙星对鸡败血支原体与大肠杆菌合并感染的药效学研究[J]. 中国兽药杂志, 2001, 35(1):9-12.
ZHANG X Y, GUO W X, TONG H M, et al. Pharmacodynamic studies of danofloxacin in chicks infected with Mycoplasma gallisepticum and E. coil[J]. Chinese Journal of Veterinary Drug, 2001, 35(1):9-12. (in Chinese)
[76] DEGUCHI T, KIKUCHI M, YASUDA M, et al. Sitafloxacin:Antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV[J]. J Infect Chemother, 2015, 21(1):74-75.
[77] DING H, WANG L, SHEN X, et al. Plasma and tissue pharmacokinetics of marbofloxacin in experimentally infected chickens with Mycoplasma gallisepticum and Escherichia coli[J]. J Vet Pharmacol Ther, 2013, 36(5):511-515.
[78] 李红萍, 邹勇, 帅华平. 鸡霉形体病的诊治[J]. 福建畜牧兽医, 2009, 31(1):35-36.
LI H P, ZOU Y, SHUAI H P. Diagnosis and treatment of Mycoplasma gallisepticum[J]. Fujian Journal of Animal Husbandry and Veterinary Medicine, 2009, 31(1):35-36. (in Chinese)
[79] 吴孔兴, 陈峰. 鸡霉形体病的诊断与防制[J]. 当代畜禽养殖业, 2003(4):52-54.
WU K X, CHEN F. Diagnosis and control of Mycoplasma gallisepticum disease[J]. Modern Animal Husbandry, 2003(4):52-54. (in Chinese)
[80] 张君慧, 牛华锋, 郝春燕. 鸡的传染性滑膜囊炎的诊治[J]. 畜牧兽医杂志, 2010, 29(1):101, 103.
ZHANG J H, NIU H F, HAO C Y. Diagnosis and treatment of infectious synovitis of chickens[J]. Journal of Animal Science and Veterinary Medicine, 2010, 29(1):101, 103. (in Chinese)
[81] 毛战胜. 鸡败血霉形体病因分析及综合防制[J]. 中国家禽, 2009, 31(3):49, 51.
MAO Z S. Cause analysis and integrated control of Mycoplasma galliseplicum infection in chicken[J]. China Poult, 2009, 31(3):49, 51. (in Chinese)
[82] 李耘, 郑波, 吕媛, 等. 新抗菌药物临床试验折点制定方案专家共识[J]. 中国临床药理学杂志, 2015, 31(11):1069-1076.
LI Y, ZHENG B, LV Y, et al. Chinese experts' consensus on protocol of breakpoints setting of new antibacterial agents for clinical trial[J]. The Chinese Journal of Clinical Pharmacology, 2015, 31(11):1069-1076. (in Chinese)